SCHEDULE: Vanguard Group Reports Zero AnaptysBio Stake

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in AnaptysBio Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for AnaptysBio Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0% of AnaptysBio Inc.'s common stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these separate subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for AnaptysBio Inc. as it primarily reflects an internal administrative change in how The Vanguard Group reports its beneficial ownership, rather than a change in investment strategy or a full divestment by all Vanguard entities.

Risks

• Investors might misinterpret the 0% beneficial ownership reported by 'The Vanguard Group' as a complete divestment by all Vanguard entities, potentially leading to unwarranted concern, despite the filing clarifying it's an internal reporting realignment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like Vanguard are administrative and common, reflecting changes in internal reporting structures rather than a strategic shift in investment thesis regarding AnaptysBio. It does not imply a change in the overall institutional interest in AnaptysBio from Vanguard's broader family of funds.

Stakeholder Impact

• Shareholders: May initially misinterpret the 0% ownership reported by 'The Vanguard Group' as a complete exit, but understanding the context of internal realignment should mitigate concern. The overall Vanguard family of funds may still hold shares through different reporting entities.

Key Dates

Recommendation

This filing is an administrative update from The Vanguard Group regarding its internal reporting structure for beneficial ownership. It does not reflect a change in AnaptysBio's fundamentals or a strategic divestment by Vanguard's broader investment vehicles. Therefore, it provides no new information to warrant a change in investment recommendation for AnaptysBio.

Keywords

AnaptysBio Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Internal Realignment